A spontaneous mutation involving Kcnq2 (Kv7.2) reduces M-current density and spike frequency adaptation in mouse CA1 neurons

被引:69
作者
Otto, JF
Yang, Y
Frankel, WN
White, HS
Wilcox, KS
机构
[1] Univ Utah, Dept Pharmacol & Toxicol, Anticonvulsant Drug Dev Program, Salt Lake City, UT 84112 USA
[2] Jackson Lab, Bar Harbor, ME 04609 USA
关键词
M-current; KCNQ2; C-terminal deletion; spike frequency adaptation; BFNC; retigabine;
D O I
10.1523/JNEUROSCI.1575-05.2006
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The M-type K+ current [I-K(M)] activates in response to membrane depolarization and regulates neuronal excitability. Mutations in two subunits (KCNQ2 and KCNQ3; Kv7.2 and Kv7.3) that underlie the M-channel cause the human seizure disorder benign familial neonatal convulsions (BFNC), presumably by reducing IK( M) function. In mice, the Szt1 mutation, which deletes the genomic DNA encoding the KCNQ2 C terminus and all of CHRNA4 (nicotinic acetylcholine receptor alpha 4 subunit) and ARFGAP-1 (GTPase-activating protein that inactivates ADP-ribosylation factor 1), reduces seizure threshold, and alters M-channel pharmacosensitivity. Genomic deletions affecting the C terminus of KCNQ2 have been identified in human families with BFNC, and truncation of the C terminus prevents proper KCNQ2/KCNQ3 channel assembly in Xenopus oocytes. We showed previously that Szt1 mice have a reduced baseline seizure threshold and altered sensitivity to drugs that act at the M-channel. Specifically, the proconvulsant M-channel blocker linopirdine and anticonvulsant enhancer retigabine display increased and decreased potency, respectively, in Szt1 mice. To investigate the effects of the Szt1 mutation on IK( M) function explicitly, perforated-patch electrophysiology was performed in CA1 pyramidal neurons of the hippocampus in brain slices prepared from C57BL/6J-Szt1/+ and control C57BL/6J+/+ mice. Our results show that Szt1 reduces both I-K(M) amplitude and current density, inhibits spike frequency adaptation, and alters many aspects of M-channel pharmacology. This is the first evidence that a naturally occurring Kcnq2 mutation diminishes the amplitude and function of the native neuronal I-K(M), resulting in significantly increased neuronal excitability. Finally, the changes in single-cell biophysical properties likely underlie the altered seizure threshold and pharmacosensitivity reported previously in Szt1 mice.
引用
收藏
页码:2053 / 2059
页数:7
相关论文
共 37 条
[1]   REDUCTION OF SPIKE FREQUENCY ADAPTATION AND BLOCKADE OF M-CURRENT IN RAT CA1 PYRAMIDAL NEURONS BY LINOPIRDINE (DUP-996), A NEUROTRANSMITTER RELEASE ENHANCER [J].
AIKEN, SP ;
LAMPE, BJ ;
MURPHY, PA ;
BROWN, BS .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 115 (07) :1163-1168
[2]   The effect of CGX-1007 and CI-1041, novel NMDA receptor antagonists, on NMDA receptor-mediated EPSCs [J].
Barton, ME ;
White, HS ;
Wilcox, KS .
EPILEPSY RESEARCH, 2004, 59 (01) :13-24
[3]   How mutations in the nAChRs can cause ADNFLE epilepsy [J].
Bertrand, D ;
Picard, F ;
Le Hellard, S ;
Weiland, S ;
Favre, I ;
Phillips, H ;
Bertrand, S ;
Berkovic, SF ;
Malafosse, A ;
Mulley, J .
EPILEPSIA, 2002, 43 :112-122
[4]   A potassium channel mutation in neonatal human epilepsy [J].
Biervert, C ;
Schroeder, BC ;
Kubisch, C ;
Berkovic, SF ;
Propping, P ;
Jentsch, TJ ;
Steinlein, OK .
SCIENCE, 1998, 279 (5349) :403-406
[5]   MUSCARINIC SUPPRESSION OF A NOVEL VOLTAGE-SENSITIVE K+ CURRENT IN A VERTEBRATE NEURON [J].
BROWN, DA ;
ADAMS, PR .
NATURE, 1980, 283 (5748) :673-676
[6]   Benign familial neonatal convulsions caused by altered gating of KCNQ2/KCNQ3 potassium channels [J].
Castaldo, P ;
del Giudice, EM ;
Coppola, G ;
Pascotto, A ;
Annunziato, L ;
Taglialatela, M .
JOURNAL OF NEUROSCIENCE, 2002, 22 (02)
[7]   M-CURRENTS IN VOLTAGE-CLAMPED MAMMALIAN SYMPATHETIC NEURONS [J].
CONSTANTI, A ;
BROWN, DA .
NEUROSCIENCE LETTERS, 1981, 24 (03) :289-294
[8]   KCNQ2 is a nodal K+ channel [J].
Devaux, JJ ;
Kleopa, KA ;
Cooper, EC ;
Scherer, SS .
JOURNAL OF NEUROSCIENCE, 2004, 24 (05) :1236-1244
[9]  
Dost R, 2000, EPILEPSY RES, V38, P53
[10]  
FLAGMEYER I, 1995, ARZNEIMITTEL-FORSCH, V45-1, P456